Bayer and Hologic have announced a collaborative effort to enhance the technology and accessibility of contrast-enhanced mammography (CEM), a promising development in the field of breast imaging.

The companies will bring together Hologic's advanced mammography systems with Bayer's MEDRAD Stellant FLEX CT Injection System, which is notably the only CT injection system cleared by the FDA for CEM applications. The partnership aims to simplify the acquisition and setup process for healthcare facilities, making CEM more accessible to imaging providers.

The news follows a September 2023 announcement from the companies, indicating they would begin working together on a CEM international partnership.
CEM is gaining recognition for its sensitivity and cost-effectiveness in breast cancer screening. It is particularly useful in ambiguous cases where traditional imaging methods may fall short. The technology allows for more detailed imaging, facilitating early and accurate detection which is critical in the effective management and treatment of breast cancer.

The collaboration was revealed at the Society of Breast Imaging Symposium held in Montreal, Canada.

The American Cancer Society estimates that in 2024 alone, over 310,000 women will be diagnosed with invasive breast cancer in the U.S. The integration of CEM into regular clinical practice is supported by a growing body of independent research, underscoring its potential as a valuable adjunct to conventional mammography.

A study by the American College of Radiology called the Contrast Enhanced Mammography Imaging Screening Trial (CMIST) is currently underway and aims to determine whether CEM improves breast cancer detection for women with dense breasts.

Women's Health Homepage